Subscribe
shutterstock_1643947495_andrii_vodolazhskyi
Andrii Vodolazhskyi / Shutterstock.com
1 September 2020AsiaMao Xiao Hong and Danny Yap

COVID-19: Protection of IP for AI tools

Nine days before the World Health Organization officially notified the public of a flu-like outbreak in China, BlueDot, a Canadian artificial intelligence (AI) startup, warned its clients of a potential outbreak near a market in Wuhan, China.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Bioinformatics: a guide to IP protection
12 June 2023   AI and computer-related inventions that use biological data are hot property, but what IP is best to protect them? Lauris Kemp, Claire Irvine, and Susan Keston of HGF explain.
Europe
UK implored to back COVID-19 IP waiver at WTO
11 March 2021   The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.
Big Pharma
What 2020 means for the life sciences
15 December 2020   Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Biotechnology
Bioinformatics: a guide to IP protection
12 June 2023   AI and computer-related inventions that use biological data are hot property, but what IP is best to protect them? Lauris Kemp, Claire Irvine, and Susan Keston of HGF explain.
Europe
UK implored to back COVID-19 IP waiver at WTO
11 March 2021   The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.
Big Pharma
What 2020 means for the life sciences
15 December 2020   Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

More on this story

Biotechnology
Bioinformatics: a guide to IP protection
12 June 2023   AI and computer-related inventions that use biological data are hot property, but what IP is best to protect them? Lauris Kemp, Claire Irvine, and Susan Keston of HGF explain.
Europe
UK implored to back COVID-19 IP waiver at WTO
11 March 2021   The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.
Big Pharma
What 2020 means for the life sciences
15 December 2020   Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Bankruptcy judge approves $305m sale of genetics testing company
Broad Institute wins appeal to restore CRISPR patent in Europe
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Regeneron hits Amgen over its blockbuster eye disease treatment
Diverging in the detail: UPC local divisions and Court of Appeal take different paths